Organ involvement | ||||
---|---|---|---|---|
All patients | Lung | Skin | Eye | |
Number | 207 | 184 | 54 | 45 |
Age, years, mean (SD) | 48 (11) | 48 (11) | 47 (9) | 49 (13) |
Women, n (%) | 112 (54) | 98 (53) | 31 (57) | 28 (62) |
Ethnicity, n (%) | ||||
Caucasian | 120 (58) | 105 (57) | 17 (31) | 19 (42) |
Afro-Caribbean | 62 (30) | 57 (31) | 30 (57) | 20 (44) |
South Asian* | 21 (10) | 18 (10) | 5 (9) | 5 (11) |
Other | 4 (2) | 4 (2) | 2 (4) | 1 (3) |
Smoking status, n (%) | ||||
Current | 25 (12) | 24 (13) | 3 (6) | 3 (7) |
Ex | 56 (27) | 51 (28) | 13 (24) | 16 (35) |
Never | 126 (61) | 109 (59) | 38 (70) | 26 (58) |
Time since diagnosis, years, mean (SD) | 7.7(6.6) | 7.5 (6.2) | 6.9 (4.9) | 6.9 (5.9) |
Organs involved, n (%) | ||||
Lungs | 184 (89) | |||
Skin | 54 (26) | |||
Eyes | 45 (22) | |||
Nervous system | 9 (4) | |||
Ear, nose and throat | 7 (3) | |||
Liver | 8 (4) | |||
Lymph nodes | 6 (3) | |||
Bone and joints | 17 (8) | |||
Other | 14 (7) | |||
Number of organs involved | 1.8 (0.9) | 1.8 (0.9) | 2.6 (0.9) | 2.7 (0.8) |
Physician Global Assessment (Skin) | 1.4 (0.93) | |||
Visual acuity (best eye), n (%) | ||||
Normal | 25 (56) | |||
Moderate impairment | 14 (31) | |||
Severe impairment | 6 (13) | |||
FEV1% predicted, mean (SD) | 76 (24) | |||
FVC% predicted, mean (SD) | 93 (18) | |||
TLCO% predicted, mean (SD) | 63 (16) | |||
Immunosuppressant, n (%) | ||||
None | 60 (29) | |||
Prednisolone | 139 (67) | |||
Methotrexate | 29 (14) | |||
Azathioprine | 29 (14) | |||
Hydroxychloroquine | 27 (13) | |||
Other immunosuppression | 2 (1) |
*South Asian patients originating from India, Pakistan or Bangladesh.
Visual acuity: normal: <20/30; moderate impairment: >20/30 but <20/63; severe impairment: >20/63.
Immunosuppressant medications were those prescribed at the time of the study.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLCO, diffusing capacity of the lung for carbon monoxide as % predicted.